Stock listing
TASE:PPBT Purple Biotech Ltd. מניה
Home listing (TASE) of Purple Biotech Ltd.
Follow Purple Biotech Ltd. into a list and get an email when it puts out news.
Share price · TASE:PPBT
1.00 ILA (agorot) 0.00 (0.0%)
Close on Nov 19, 2026
- Day range
- 1.00 – 1.00 ILA (agorot)Nov 19, 2026
- Market cap
- 32.54M ILSAt the close on Nov 19, 2026 · price × 3.25B shares outstanding
- 52-week range
- 1.00 – 1.60 ILA (agorot)Lowest and highest trades, Nov 20, 2025 – Nov 19, 2026
- Traded on an average day
- 157 ILSMedian day 0 shares · 54 days with no trades · last 3 months, Aug 19, 2026 – Nov 19, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| TASE:PPBT · Home | 1.00 ILA (agorot) | 0.00 (0.0%) | — | 1.00 | 1.00 | 1.00 | 1.00 | Close on Nov 19, 2026 |
| NASDAQ:PPBT | $1.525 USD | -0.005 (-0.3%) | 21,776 | $1.50 | $1.56 | $1.29 | $1.53 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 19, 2026 – Nov 19, 2026 · TASE:PPBT · ILA (agorot), adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 100,000 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 250,000 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 100,000 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 50,000 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 11,000 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 150,000 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 300,000 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 30,000 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 1,000 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 |
Splits
3 splits since 2012 · TASE:PPBT · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-20 | Consolidation | |
| 1-for-13 | Consolidation | |
| 1-for-100 | Consolidation |
- Ticker
- TASE:PPBT
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- TASE
- Currency
- ILA
What changed lately
Latest news release · Apr 27, 2026
Purple Biotech Announces New Data from CAPTN-3 Platform Tri-specific IM1240
Latest deck · Aug 10, 2026
Investor Presentation (August 2026)
Investor deck · 45 slides
Latest news
Purple Biotech Announces New Data from CAPTN-3 Platform Tri-specific IM1240
Apr 27, 2026
Closed 1.00 (0.0%) on Apr 27, 2026
Purple Biotech Establishes Scientific Advisory Board to Support Development of CAPTN-3 Tri-Specific Antibody Platform
Apr 23, 2026
Closed 1.00 (0.0%) on Apr 23, 2026
Purple Biotech Announces AI Collaboration with Converge Bio to Accelerate Development of its Next-Generation Tri-Specific Antibody Platform
Mar 25, 2026
Closed 1.00 (0.0%) on Mar 25, 2026
Purple Biotech Regains Compliance with Nasdaq
Mar 17, 2026
Closed 1.00 (0.0%) on Mar 17, 2026
Purple Biotech Announces CEO Transition
Mar 13, 2026
Closed 1.00 (0.0%) on Mar 13, 2026
Purple Biotech Announces Plan to Implement ADS Ratio Change
Feb 25, 2026
Closed 1.00 (0.0%) on Feb 26, 2026
Purple Biotech Achieves Toxicology Milestone Demonstrating an Expanded Therapeutic Window for CAPTN-3 Platform Tri-specific Antibody, IM1240
Jan 7, 2026
Closed 1.20 (0.0%) on Jan 7, 2026
Purple Biotech Reports Positive New Preclinical Data Demonstrating Multi-Arm Anti-Tumor Activity Across Two CAPTN-3 Tri-Specific Antibodies at ESMO Immuno-Oncology Congress 2025
Dec 11, 2025
Closed 1.40 (+7.7%) on Dec 11, 2025
Purple Biotech Ltd. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 9 in the last 12 months · 32 in all · newest Apr 27, 2026 · oldest 2025
- Decks
- 56 decks · latest Aug 10, 2026
Where Purple Biotech Ltd. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| TASE:PPBT · Home listing · This page | TASE | Israel | ILA |
| NASDAQ:PPBT | NASDAQ | United States | USD |
| BOATS:PPBT | BOATS | United States | USD |
| gettex:1YI0 | gettex | Germany | EUR |
| Frankfurt:1YI0 | Frankfurt | Germany | EUR |
| Lang & Schwarz:A40NWE | Lang & Schwarz | Germany | EUR |
| Munich:1YI0 | Munich | Germany | EUR |
| Stuttgart:IL0007650166 | Stuttgart | Germany | EUR |
Valuation
Price/book 0.8× against a median of 0.6×: 5th lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 19, 2026
- Enterprise value
- 12.50M ILS
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.8×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Purple Biotech Ltd. · TASE:PPBT | US$9.70M | US$3.73M | n/a | n/a | n/a | 0.8× | n/a | 0.0× | n/a |
| Ceryvyn Therapeutics Limited · ASX:CYV | US$9.96M | −US$9.91M | 0.1× | −14,971× | n/a | 0.5× | n/a | 0.0× | n/a |
| aTyr Pharma, Inc. · NASDAQ:ATYR | US$9.74M | −US$28.09M | n/a | n/a | n/a | 0.3× | n/a | 0.3× | 2.12 |
| Lisata Therapeutics, Inc. · NASDAQ:LSTA | US$9.71M | −US$273.0M | n/a | −2,730× | n/a | 1.3× | n/a | 0.0× | 0.71 |
| Jasper Therapeutics, Inc. · NASDAQ:JSPR | US$9.64M | −US$125.6M | n/a | −15.7× | n/a | n/a | n/a | n/a | 2.02 |
| Chemomab Therapeutics Ltd. · NASDAQ:CMMB | US$9.58M | US$4.92M | n/a | n/a | n/a | 2.6× | n/a | 0.0× | 1.04 |
| Alzinova AB · OMXSTO:ALZ | US$9.57M | US$8.34M | n/a | 17.0× | n/a | 0.6× | −484.4% | 0.0× | n/a |
| Genvor Incorporated · OTC:GNVR | US$9.47M | US$9.27M | n/a | n/a | n/a | n/a | n/a | n/a | 0.44 |
| Poxel SA · EURONEXT:POXEL | US$9.27M | US$73.95M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| TScan Therapeutics, Inc. · NASDAQ:TCRX | US$9.27M | −US$30.80M | n/a | −5.9× | n/a | 0.2× | n/a | 0.9× | 1.66 |
| Rapid Dose Therapeutics Corp · CSE:DOSE | US$9.13M | US$9.12M | n/a | 5.1× | n/a | n/a | −123.1% | n/a | 0.64 |
| Median of the others | US$9.57M | −US$2.49M | 0.1× | −10.8× | 0.6× | −303.7% | 0.0× | 1.04 |
Team and board
Officers
| Officer | Role |
|---|---|
| Isaac Israel | Interim Chief Executive Officer |
| Shai Lankry | Chief Financial Officer |
| Hadas Reuveni | Vice President Research & Development |
| Michael Schickler | Head of Clinical and Regulatory Affairs |
Board
| Director | Role |
|---|---|
| Eric Rowinsky | Chairman of the Board |
| Ido Agmon | Board Member |
| Isaac Israel | Interim Chief Executive Officer |
| Robert Gagnon | Board Member |
| Suzana Nahum-Zilberberg | Board Member |
| Yael Margolin | Board Member |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (August 2026) | Investor deck | 45 slides | Aug 10, 2026 |
| Investor Presentation (June 2026) | Investor deck | 45 slides | Jun 23, 2026 |
| Investor Presentation (March 2026) | Investor deck | 59 slides | Mar 19, 2026 |
| Investor Presentation (January 2026) | Investor deck | 62 slides | Jan 13, 2026 |
| Investor Presentation (January 2026) | Investor deck | 59 slides | January 2026 |
| Investor Presentation (November 2025) | Investor deck | 57 slides | Nov 19, 2025 |
| Investor Presentation (September 2025) | Investor deck | 56 slides | Sep 16, 2025 |
| Investor Presentation (July 2025) | Investor deck | 55 slides | July 2025 |
| Investor Presentation (May 2025) | Investor deck | 59 slides | May 6, 2025 |
| Investor Presentation (March 2025) | Investor deck | 58 slides | Mar 18, 2025 |
Show 50 decks
This page holds 50 of 56 decks. Open Decks
Financings
| Raise | Date |
|---|---|
| Public offering of american Depositary Shares (or pre-funded warrants) and short-term warrants Closed: US$6M raised · US$1 a share · Warrants at US$1 for 24 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Development of its oncology therapeutic candidates and general working capital and corporate purposes | Sep 5, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as Kitov Pharmaceuticals Holdings Ltd. Priced at US$4.12 an ADS on Nov 23, 2015.
- Price
- US$4.12 an ADS
- ADSs offered
- 3,158,900 American depositary shares
- Offering size
- US$13 million
- Underwriters' option
- Up to 473,835 more ADSs
- Listing
- KTOV on the Nasdaq Capital Market
- Underwriters
- Rodman & Renshaw, Joseph Gunnar & Co. · In the order on the cover
- ADSs delivered
- On or about Nov 25, 2015
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Aug 18, 2014 |
| Filed publicly | Sep 24, 2015 |
| Amended 4 times | Newest Nov 20, 2015 |
| Shares registered with an exchange | Nov 18, 2015 |
| Declared effective by the SEC | Nov 20, 2015 |
| Final prospectus, with the price | Nov 23, 2015 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Nov 23, 2015 |
| EFFECT · Notice that a registration is effective | Nov 20, 2015 |
| F-1MEF · Registration of more shares for the same offering | Nov 20, 2015 |
| F-1/A · Registration statement, amended | Nov 20, 2015 |
| CERTNAS · Nasdaq's certificate of listing | Nov 19, 2015 |
| F-1/A · Registration statement, amended | Nov 19, 2015 |
| UPLOAD · Letter from the SEC | Nov 18, 2015 |
| F-1/A · Registration statement, amended | Nov 18, 2015 |
| 8-A12B · Registration of shares for listing on an exchange | Nov 18, 2015 |
| CORRESP · Letter to the SEC | Nov 17, 2015 |
All 19 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Nov 17, 2015 |
| FWP · Free writing prospectus | Nov 12, 2015 |
| F-1/A · Registration statement, amended | Nov 6, 2015 |
| F-1 · Registration statement | Sep 24, 2015 |
| DRS/A · Draft registration statement, amended | Aug 21, 2015 |
| DRSLTR · Letter to the SEC with a draft | Aug 21, 2015 |
| UPLOAD · Letter from the SEC | Aug 12, 2015 |
| DRS · Draft registration statement | Jul 20, 2015 |
| DRS · Draft registration statement | Aug 18, 2014 |
Open IPO · From the cover of the final prospectus (424B4) filed Nov 23, 2015
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 195.8K | 0 | 0 | 1.00M | 1.00M | 1.00M | 100.0K | |
| Cost of revenue | 219.7K | 62.0K | 196.0K | 120 | 55 | 58 | 80 | |||
| Gross profit | -219.7K | -62.0K | -196 | -120 | -55 | 999.9K | 999.9K | 1.00M | ||
| Research and development | 3.73M | 7.62M | 17.0M | 16.3M | 11.8M | 7.24M | 2.28M | 5.27M | 4.64M | 4.18M |
| Selling, general and administrative | 3.25M | 3.18M | 5.24M | 6.28M | 6.11M | 6.00M | 4.39M | 5.20M | 6.40M | 3.00M |
| Operating income | -27.5M | -11.0M | -22.3M | -22.6M | -17.9M | -12.6M | -7.16M | -7.83M | -12.0M | -7.18M |
| Depreciation and amortization | 203.0K | 186.0K | 197.0K | 201.0K | 231.0K | 235.0K | 178.0K | 7.00K | 4.00K | 2.00K |
| EBITDA | -27.3M | -10.8M | -22.1M | -22.4M | -17.7M | -12.4M | -6.98M | -7.82M | -12.0M | -7.18M |
| Interest expense | 982.0K | 483.0K | 2.19M | 67.0K | -212.0K | 61.0K | 181.0K | 576.0K | 26.0K | 61.0K |
| Income before tax | -26.5M | -7.28M | -20.0M | -21.8M | -17.8M | -28.7M | -5.89M | -5.57M | ||
| Income tax | 216.0K | |||||||||
| Net income | -26.4M | -7.24M | -19.9M | -21.7M | 18.4M | 28.0M | 5.85M | 5.20M | 12.2M | 12.1M |
| Earnings per share, basic | 0.03 | 4.44 | 17.96 | 23.97 | 17,568,036.00 | 0.16 | 0.30 | 0.37 | ||
| Earnings per share, diluted | 0.03 | 4.99 | 17.96 | 23.97 | 17,568,036.00 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 8.72M | 7.40M | 14.5M | 15.0M | 10.9M | 11.2M | 4.38M | 5.16M | 3.95M | 6.76M |
| Short-term investments | 857.2K | 275.0K | 73.0K | 431.0K | 36.3M | 46.6M | 2.01M | 1.52M | ||
| Receivables | 155.0K | 275.0K | 500.0K | 1.49M | 743.0K | |||||
| Inventory | -1.49M | 778.0K | ||||||||
| Current assets | 9.87M | 8.91M | 15.8M | 33.3M | 48.5M | 59.3M | 8.30M | 8.51M | 7.98M | 14.9M |
| Property, plant and equipment | 124.0K | 124.0K | 154.0K | 215.0K | 277.0K | 178.0K | 38.0K | 37.0K | 28.0K | 16.0K |
| Goodwill | 20.7M | 20.5M | 20.5M | |||||||
| Total assets | 17.6M | 37.0M | 44.3M | 54.6M | 70.2M | 83.8M | 14.7M | 14.7M | 14.2M | 14.9M |
| Accounts payable | 2.07M | 1.46M | 3.53M | 2.13M | 1.47M | 1.20M | 1.25M | 705.0K | 215.0K | 515.0K |
| Current liabilities | 7.75M | 3.99M | 9.70M | 7.06M | 4.25M | 3.10M | 3.55M | 3.31M | 3.97M | 1.27M |
| Total debt | 244.1K | 183.0K | 351.0K | 515.0K | 749.0K | 895.0K | 223.0K | |||
| Total liabilities | 7.91M | 4.13M | 10.0M | 7.52M | 5.09M | 4.05M | 3.86M | 3.72M | ||
| Shareholders' equity | 9.71M | 32.9M | 34.2M | 46.9M | 64.8M | 79.4M | 10.4M | 10.5M | 7.41M | 13.4M |
| Shares outstanding | 960.1M | 517.1M | 246.2M | 184.8M | 178.0M | 172.1M | 19.4M | 14.2M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -5.66M | -14.4M | -19.9M | -16.7M | -374.0K | 1.71M | -1.97M | -8.48M | -8.63M | -6.26M |
| Capital spending | -3.00K | 0 | -3.00K | -26.0K | -115.0K | -156.0K | -11.0K | -16.0K | -13.0K | -10.0K |
| Free cash flow | -5.66M | -14.4M | -19.9M | -16.8M | -489.0K | 1.55M | -1.98M | -8.50M | -8.64M | -6.27M |
| Cash from investing | 632.0K | 509.0K | 13.9M | 19.9M | 13.4M | -49.6M | -449.0K | 2.04M | 2.77M | -7.77M |
| Cash from financing | 6.33M | 6.77M | 5.45M | 1.11M | 1.51M | 68.5M | 5.23M | 7.79M | 3.00M | 10.3M |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Change in cash | 1.31M | -7.08M | -595.0K | 4.29M | -333.0K | 6.80M | -797.0K | 1.35M | -2.86M | -3.75M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 6-K · Report of a foreign issuer | Nov 20, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 17, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 12, 2026 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Nov 12, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 10, 2026 | Big-stake notice | SEC |
| F-3/A · Registration statement, amended | Nov 6, 2026 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Oct 5, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 9, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 2, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
Show 200 filings
This page holds 200 of 582 filings. Open Filings
Cap table
Built by 6ix from Purple Biotech Ltd.’s releases · as of Sep 5, 2025
- Common shares
- 3,253,734,117
- Fully diluted
- 3,253,734,117
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 3,253,734,117 |
Warrants and options
| Lot |
|---|
| Warrants · US$1.00 · expire about Sep 2027 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 3,253,734,117 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Robert Gagnon Other companies: Opus Genetics, Inc. (Chief Financial Officer · Since at least Sep 2, 2025); Bone Biologics Corp (Director · Since at least Jan 8, 2024); Verastem, Inc. (Director · Since at least Aug 28, 2018); Harvard Bioscience, Inc. (Director · Since at least Nov 18, 2013); Clean Harbors, Inc. (EVP CFO and Treasurer · Aug 20, 2012 – Sep 11, 2012 · Past); Biogen Inc. (Vice President, Finance · Nov 3, 2010 – Feb 28, 2012 · Past) | Board Member · Since at least Mar 18, 2026 |
| Eric K. Rowinsky Other companies: Verastem, Inc. (Director · Since at least Jun 21, 2019); Biogen Inc. (Director · Since at least Jun 19, 2019); Fortress Biotech, Inc. (Director · Jan 1, 2019 – Jan 1, 2024 · Past) | Chairman of the Board · Since at least Mar 13, 2026 |
| Gil Efron | Executive Director, Head of Corporate Development · Until Mar 13, 2026 · Past |
| Gil Efron | Chief Executive Officer · Since at least Mar 18, 2026 |
| Hadas Reuveni | Vice President Research & Development · Since at least Dec 11, 2025 |
| Ido Agmon | Board Member · Since at least Mar 18, 2026 |
| Isaac Israel | Interim Chief Executive Officer · Since at least Nov 6, 2026 |
| Michael Schickler | Head of Clinical and Regulatory Affairs · Since at least Oct 29, 2025 |
| Shai Lankry | Chief Financial Officer · Since at least May 12, 2025 |
| Suzana Nahum-Zilberberg | Board Member · Since at least Nov 6, 2026 |
All 11 people
| Person | Seat |
|---|---|
| Yael Margolin | Board Member · Since at least Nov 6, 2026 |
Log in to ask 6ix AI your own questions about Purple Biotech Ltd.